Organisation paid for research Program year 2025 Source: CMS Open Payments

Florida Research Center Inc

Neither a doctor nor a teaching hospital

Research payments

$2,108,775

242 payments

Through program year 2025, Florida Research Center Inc is reported as receiving $2,108,775 in research payments, across 242 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $137,578 24
2024 Research $164,571 25
2023 Research $134,155 30
2022 Research $315,636 49
2021 Research $312,585 35
2020 Research $491,422 42
2019 Research $552,828 37

Breakdown

Who paid Research payments · program years 2019–2025
  1. Janssen Research & Development, LLC $698,674 47 payments
  2. Eli Lilly and Company $506,133 8 payments
  3. ACADIA Pharmaceuticals Inc $324,622 35 payments
  4. AbbVie, Inc. $227,020 83 payments
  5. H. Lundbeck A S $207,295 45 payments
  6. Galderma Laboratories, L.P. $109,291 12 payments
  7. GlaxoSmithKline, LLC. $17,441 6 payments
  8. Allergan Inc. $10,500 3 payments
  9. Genentech, Inc. $7,800 3 payments
Studies the money was for Research payments · program years 2019–2025
  1. An Open-label Long-term Extension Safety Study of Intranasal Esketamine in Treatment-resistant Depression $605,575 25 payments
  2. A Phase 3, 16-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Assess the Impact of Lebrikizumab on Vaccine Responses in Adult Patients With Moderate-To-Severe Atopic Dermatitis $211,242 2 payments
  3. A Long-Term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-To-Severe Atopic Dermatitis $207,066 4 payments
  4. Acp-103-059 $205,713 18 payments
  5. A Clinical Study of Patients With Symptomatic Neurogenic Orthostatic Hypotension to Assess Sustained Effects of Droxidopa Therapy $136,756 41 payments
  6. A Prospective, Multicenter, Long-Term Study to Assess the Safety and Efficacy of Nemolizumab (CD14152) in Subjects With Moderate-to-Severe Atopic Dermatitis $109,291 12 payments
  7. Acp-103-055 $103,909 15 payments
  8. Sustained Effect of Droxidopa in Symptomatic Neurogenic Orthostatic Hypotension RESTORE $67,939 1 payment
  9. A Study of the Change in Disease State and Safety of Oral Cariprazine Capsules in the Treatment of Depression in Pediatric Participants (10 to 17 Years of Age) With Bipolar I Disorder $66,584 18 payments
  10. A Long-Term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-To-Severe Atopic Dermatitis $66,529 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record